Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era
- PDF / 1,247,665 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 6 Downloads / 180 Views
RESEARCH ARTICLE
Open Access
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative Marta Soares1* , Luís Antunes2 , Patrícia Redondo3 , Marina Borges3 , Ruben Hermans4, Dony Patel4, Fiona Grimson4, Robin Munro4, Carlos Chaib5, Laure Lacoin6, Melinda Daumont7, John R. Penrod8, John C. O’Donnell8, Maria José Bento2,9 and Francisco Rocha Gonçalves10
Abstract Background: As part of the multinational I-O Optimise research initiative, this retrospective cohort study of patients with advanced non-small cell lung cancer (NSCLC) evaluated real-world treatment patterns and survival prior to immunotherapy reimbursement in Portugal. Methods: This study utilized a database held by IPO-Porto, Portugal’s largest oncology hospital. Adult patients diagnosed with stage IIIB or IV NSCLC from January 2012 to December 2016 at IPO-Porto, with follow-up to June 2017, were included. Treatment analyses were performed from 2015 onwards. Kaplan–Meier methods were used for overall survival (OS). Factors associated with OS and systemic anti-cancer therapy (SACT) treatment were assessed using multivariate statistical models. (Continued on next page)
* Correspondence: [email protected] 1 Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr. Antonio Bernardino de Almeida, 4200-072 Porto, Portugal Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Soares et al. BMC Pulmonary Medicine
(2020) 20:240
Page 2 of 13
(Continued from previous page)
Results: Of 1524 patients diagnosed with NSCLC at IPO-Porto, 1008 patients had advanced disease (stage IIIB: 10.1%, 154/1524, stage IV: 56.0%, 854/1524). For those with advanced disease, median age was 65 years (range: 21– 92) and 75.6% (762/1008) were male. Median OS (interquartile range [IQR]) was 11.4 (5.2–26.9) months for stag
Data Loading...
